GlassScriptPhysician profile
Bethany A Winter
NPI 1568068989
$1,549.93
in general payments reported to CMS, 2019-2025
15 companies · $16.05 in 2025
The $16.05 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $91.34 · 2023: $740 · 2024: $703 · 2025: $16.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $149.45 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ferring Pharmaceuticals INC. | $147.30 | 2023 | Rebyota |
| Alexion Pharmaceuticals, INC. | $133.83 | 2024 | |
| Phathom Pharmaceuticals, INC. | $130.39 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $126.65 | 2024 | Inspire |
| Abbvie INC. | $124.99 | 2023 | |
| Janssen Pharmaceuticals, INC | $121.63 | 2024 | Xarelto |
| Genzyme Corporation | $114.06 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.97 | 2024 | |
| Neurelis, INC. | $93.14 | 2024 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $91.34 | 2022 | |
| Neurocrine Biosciences, INC. | $85.27 | 2023 | Ongentys |
| Gilead Sciences, INC. | $83.00 | 2023 | Descovy |
| Alnylam Pharmaceuticals INC. | $35.86 | 2023 | Givlaari |
| Boston Scientific Corporation | $16.05 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.